The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antisense oligonucleotides: modifications and clinical trials
Abstract
There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been synthesized because natural DNA/RNA based oligonucleotides pose some limitations, such as poor binding affinity, low degree of nuclease resistance, affecting their direct use in antisense therapeutics. In this review article, we discuss in detail different modifications of nucleosides/oligonucleotides along with the related clinical trials, which demonstrated their potential as drug candidates for antisense and related nucleic acid based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
Antisense Oligonucleotides: The State of the Art
Aboul-Fadl, T. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054864859 · Cited by 128
Sekhon, H. S., London, C. A., Sekhon, M., Iversen, P. L., & Devi, G. R. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.10.028 · Cited by 45
Cited by
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Metadata
- Authors
- Sharma, V. K., Sharma, R. K., & Singh, S. K.
- Venue
- Med. Chem. Commun.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014-08-01
- Volume
- 5
- Issue
- 10
- Pages
- 1454-1471
- ISSN
- 2040-2503 (ISSN-L)
- 2040-2511
- OpenAlex
- W1993880149
- Cited by
- 204
- References
- 4
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antisense oligonucleotides: modifications and clinical trials. https://app.cochat.ai/papers/10.1039/c4md00184b
- The paper
- Sharma, V. K., Sharma, R. K., & Singh, S. K. (2014). Antisense oligonucleotides: modifications and clinical trials. Med. Chem. Commun. https://doi.org/10.1039/c4md00184b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.